Bulk Inquiry
APD 597
- JNJ 38431055
Axon 2541
CAS:
897732-93-3
Purity:
99%
- Soluble in DMSO
- MF: C21H29N5O6S
- MW: 479.55
Description
APD 597 (JNJ 38431055) is an orally bioavailable agonist of GPR119, a metabolic GPCR expressed in pancreatic β-cells and enteroendocrine cells. It promotes incretin and insulin-related signaling relevant to glucose homeostasis.
GPR119 activation can stimulate GLP-1 release and glucose-dependent insulin secretion, making it a target for type 2 diabetes and obesity research. APD 597 is useful for studying GPR119 receptor pharmacology and incretin-regulated metabolism.
Key Features
- Selective GPR119 agonist
- Reported EC50: 44 nM at human GPR119
- Orally bioavailable pharmacology
- Designed for metabolic disease and incretin pathway research
Applications
- GPR119 receptor pharmacology
- GLP-1 and incretin signaling studies
- Pancreatic β-cell and enteroendocrine assays
- Type 2 diabetes and obesity research models
More Information
| Parent CAS No. | 897732-93-3 |
|---|---|
| Chemical Name | isopropyl 4-(5-methoxy-6-(2-methyl-6-(methylsulfonyl)pyridin-3-ylamino)pyrimidin-4-yloxy)piperidine-1-carboxylate |
| SMILES | N1(C(OC(C)C)=O)CCC(OC2C(OC)=C(NC3=CC=C(S(C)(=O)=O)N=C3C)N=CN=2)CC1 |
| MFCD | N.A. |
| InChi | InChI=1S/C21H29N5O6S/c1-13(2)31-21(27)26-10-8-15(9-11-26)32-20-18(30-4)19(22-12-23-20)25-16-6-7-17(24-14(16)3)33(5,28)29/h6-7,12-13,15H,8-11H2,1-5H3,(H,22,23,25) |
| InChiKey | WPDCHTSXOPUOII-UHFFFAOYSA-N |
| CID | 11691484 |
| Short Description | GPR119 agonist |
References
- G. Semple et al. Discovery of a second generation agonist of the orphan G-protein coupled receptor GPR119 with an improved profile. Bioorg Med Chem Lett. 2012 Feb 15;22(4):1750-5.
- L.B. Katz et al. Pharmacokinetics, pharmacodynamics, safety, and tolerability of JNJ-38431055, a novel GPR119 receptor agonist and potential antidiabetes agent, in healthy male subjects. Clin Pharmacol Ther. 2011 Nov;90(5):685-92.
- L.B. Katz et al. Effects of JNJ-38431055, a novel GPR119 receptor agonist, in randomized, double-blind, placebo-controlled studies in subjects with type 2 diabetes. Diabetes Obes Metab. 2012 Aug;14(8):709-16.
Other Categories
Get a Quote for
Loading...